Longxiang Sheng

667 total citations
11 papers, 199 citations indexed

About

Longxiang Sheng is a scholar working on Immunology, Molecular Biology and Cancer Research. According to data from OpenAlex, Longxiang Sheng has authored 11 papers receiving a total of 199 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Longxiang Sheng's work include interferon and immune responses (2 papers), Inflammasome and immune disorders (2 papers) and Glaucoma and retinal disorders (2 papers). Longxiang Sheng is often cited by papers focused on interferon and immune responses (2 papers), Inflammasome and immune disorders (2 papers) and Glaucoma and retinal disorders (2 papers). Longxiang Sheng collaborates with scholars based in China, United Kingdom and United States. Longxiang Sheng's co-authors include Guangmei Yan, Bingzheng Lu, Wei Yin, Suizhen Lin, Dongdong Xue, Wei Chi, Jiawen Luo, Chuan Bai, Yijun Huang and Lishi Su and has published in prestigious journals such as Biochemical and Biophysical Research Communications, British Journal of Pharmacology and Molecules.

In The Last Decade

Longxiang Sheng

10 papers receiving 199 citations

Peers

Longxiang Sheng
Byung Soo Kong South Korea
Cheng-Chieh Hsu United States
Yunlu Xu China
Agatha Kokot Germany
Koteswara R. Chava United States
Danli Lu China
Byung Soo Kong South Korea
Longxiang Sheng
Citations per year, relative to Longxiang Sheng Longxiang Sheng (= 1×) peers Byung Soo Kong

Countries citing papers authored by Longxiang Sheng

Since Specialization
Citations

This map shows the geographic impact of Longxiang Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longxiang Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longxiang Sheng more than expected).

Fields of papers citing papers by Longxiang Sheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longxiang Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longxiang Sheng. The network helps show where Longxiang Sheng may publish in the future.

Co-authorship network of co-authors of Longxiang Sheng

This figure shows the co-authorship network connecting the top 25 collaborators of Longxiang Sheng. A scholar is included among the top collaborators of Longxiang Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longxiang Sheng. Longxiang Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Chen, Chen, Yuwei Zhou, Longxiang Sheng, et al.. (2025). Glycolytic Enzyme HK2 Phosphorylates nSMase1 to Promote Astrocytic Exosomes Biogenesis Contributing to Acute Ischemic Stroke Injury. Advanced Science. 12(39). e01894–e01894.
2.
Zhou, Yuwei, Dongdong Xue, Zhu Zhu, et al.. (2022). Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases. Journal of Neuroinflammation. 19(1). 315–315. 42 indexed citations
3.
Xue, Dongdong, Yuehan Zhou, Kai Wang, et al.. (2022). TRIOL Inhibits Rapid Intracellular Acidification and Cerebral Ischemic Injury: The Role of Glutamate in Neuronal Metabolic Reprogramming. ACS Chemical Neuroscience. 13(14). 2110–2121. 9 indexed citations
4.
Tian, Xuyan, Lipeng Tang, Longxiang Sheng, et al.. (2021). Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells. Molecular Immunology. 132. 30–40. 12 indexed citations
5.
Deng, Yang, Longxiang Sheng, Yixin Hu, et al.. (2021). The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis. Frontiers in Cell and Developmental Biology. 9. 669696–669696. 22 indexed citations
6.
Lu, Bingzheng, Zhu Zhu, Longxiang Sheng, et al.. (2020). SMARCB1 Promotes Ubiquitination and Degradation of NR4A3 via Direct Interaction Driven by ROS in Vascular Endothelial Cell Injury. Oxidative Medicine and Cellular Longevity. 2020. 1–15. 5 indexed citations
8.
Sun, Shuxin, Dongdong Xue, Zhijie Chen, et al.. (2019). R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells. Cell Death and Disease. 10(5). 358–358. 33 indexed citations
9.
Sheng, Longxiang, Bingzheng Lu, Hui Chen, et al.. (2019). Marine-Steroid Derivative 5α-Androst-3β, 5α, 6β-triol Protects Retinal Ganglion Cells from Ischemia–Reperfusion Injury by Activating Nrf2 Pathway. Marine Drugs. 17(5). 267–267. 16 indexed citations
10.
Yan, Min, Tiandong Leng, Lipeng Tang, et al.. (2017). Neuroprotectant androst-3β, 5α, 6β-triol suppresses TNF-α-induced endothelial adhesion molecules expression and neutrophil adhesion to endothelial cells by attenuation of CYLD-NF-κB pathway. Biochemical and Biophysical Research Communications. 483(2). 892–896. 6 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026